William Blair Sticks to Its Buy Rating for Rekor Systems (REKR)
William Blair analyst Louie DiPalma maintained a Buy rating on Rekor Systems (REKR – Research Report) today. The company's shares closed today at $1.02.
Confident Investing Starts Here:
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
According to TipRanks, DiPalma is an analyst with an average return of -13.1% and a 58.39% success rate. DiPalma covers the Technology sector, focusing on stocks such as Palantir Technologies, Motorola Solutions, and Parsons.
The analyst consensus on Rekor Systems is currently a Moderate Buy rating.
Based on Rekor Systems' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $13.28 million and a GAAP net loss of $20.36 million. In comparison, last year the company earned a revenue of $11.07 million and had a GAAP net loss of $9.35 million
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
These 10 restaurant chains have the happiest workers, study finds
Among the nation's major restaurant chains, In-N-Out is still supreme when it comes to the satisfaction of its workers, according to a new study. The California-based burger chain took the top spot for a 10th straight year, according to an analysis by William Blair, an investment bank and financial services company. The annual report spans 11 years and is built on over 530,000 reviews of almost 90 restaurant brands, according to Nation's Restaurant News. This year's study found that when they weren't serving up Double-Doubles and Animal-Style fries, 91 percent of In-N-Out workers would recommend the job to a friend. The percentage marked a 5 percent jump from last year's study, according to industry publication QSR Magazine. The top three chains when it comes to employee satisfaction remained unchained from 2024 to 2025, with In-N-Out followed by Raising Cane's and Dutch Bros. Hardee's was the lowest-ranked brand at 39 percent. See the top 10 below: Rank Chain Recommendation Percentage 1. In-N-Out 91% 2. Raising Cane's 82% 3. Dutch Bros 78% 4. Chuy's 78% 5. Peet's Coffee & Tee 76% 6. Caribou Coffee 74% 7. Lazy Dog 74% 8. Portillo's 73% 9. Longhorn Steakhouse 73% 10. Chick-fil-A 72% In-N-Out is the only chain that has been in the top 10 every year for a decade, according to William Blair's analysis. So what is it that's making workers at In-N-Out, Raising Cane's and others feel good about their job? Getting a raise isn't everything, according to the study. In fact, the authors found that compensation and benefits had the lowest correlation of six measured attributes, according to Nation's Restaurant News. The top factors were instead culture/values, senior management and work/life balance. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
Citi sees Gilead clinical holds as only ‘minor setback'
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the setback impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously anticipated in 2029 or 2030. The hold does not affect Gilead's other ongoing HIV programs, including lenacapavir development for both treatment and prevention including the monthly oral combinations, as no similar lymphocyte or CD4 effects have been observed in these studies, Citi points out. As such, the firm sees the holds as a 'minor setback' and continues to believe that lenacapavir in pre-exposure prophylaxis and expansion of several differentiated lenacapavir combos should offset potential Biktarvy 2028 Inflation Reduction Act negotiations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 Gilead down 2% to $111.14 after FDA placed hold on some HIV trials Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Mixed options sentiment in CrowdStrike Holdings with shares up 0.12%
Mixed options sentiment in CrowdStrike Holdings (CRWD), with shares up 55c, or 0.12%, near $464.94. Options volume relatively light with 5050 contracts traded and calls leading puts for a put/call ratio of 0.48, compared to a typical level near 0.76. Implied volatility (IV30) dropped 0.2 near 35.4,in the bottom quartile of the past year, suggesting an expected daily move of $10.37. Put-call skew steepened, indicating increased demand for downside protection, following a downgrade to In Line at Evercore ISI. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on CRWD: Disclaimer & DisclosureReport an Issue Trump Trade: U.S., China representatives to meet about trade Cardinal Health, Dollar General, Snowflake, Constellation, and CrowdStrike: Trending by Analysts Trump signs Executive Order intended to 'strengthen the nation's cybersecurity' U.S. Layoffs Surge despite Strong Jobs Data as Major Corporations Make Cuts U.S. payrolls rise 139,000, Broadcom reports Q2 beat: Morning Buzz Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
